VEGFA and macular retinal edema: The treatment regimen was monthly IVC for 3months followed by IVC PRN (3 + PRN) in this study, but the trend of improvement in visual acuity with conbercept is similar to that with ranibizumab in the BRAVO study [11] and the CRUISE trial [12] as well as to that with aflibercept in the VIBRANT study [13] and the GALILEO study [14], all of which suggest that the effect of anti-VEGF agents on macular edema secondary to RVO occurs very soon after the initial treatment.